reports
- ABGSC Construct. & Real Estate Research
- Åsne Holsen
- Bengt Jonassen
- ABGSC Construct. & Real Estate Research
- Åsne Holsen
- Bengt Jonassen
- ABGSC Renewable Energy Research
- Åsne Holsen
- Daniel Vårdal Haugland
- ABGSC Construct. & Real Estate Research
- Åsne Holsen
- Bengt Jonassen
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Njål Kleiven
- Oliver Dunvold
- Stian Wibstad
NRC Group ASA: 1 director
A director at NRC Group ASA bought 120,000 shares at 6.000NOK and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
- ABGSC Construct. & Real Estate Research
- Åsne Holsen
- Bengt Jonassen
FRO - Grant of synthetic options
FRO - Grant of synthetic options Frontline plc ("Frontline" or the "Company") hereby announces that 362,284 synthetic options have today been granted to management and employees of the Company. The synthetic options will have a five-year term expiring May 27, 2030, and will vest over a three-year vesting period as follows: 1/3 of the synthetic options will vest on May 27, 20261/3 of the synthetic options will vest on May 27, 2027 1/3 of the synthetic options will vest on May 27, 2028 The exercise price of the synthetic options is USD 16.8 being the volume-weighted average price of the ...
FRO - Q1 2025 Presentation
FRO - Q1 2025 Presentation Please find enclosed the presentation of Frontline plc´s first quarter 2025 results to be held on the webcast / conference call 23 May, 2025 at 15:00 CET. This information is subject to the disclosure requirements pursuant to section 5 – 12 of the Norwegian Securities Trading Act. Attachment
FRO – First Quarter 2025 Results
FRO – First Quarter 2025 Results FRONTLINE PLC REPORTS RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025 Frontline plc (the “Company”, “Frontline,” “we,” “us,” or “our”), today reported unaudited results for the three months ended March 31, 2025: Highlights Profit of $33.3 million, or $0.15 per share for the first quarter of 2025.Adjusted profit of $40.4 million, or $0.18 per share for the first quarter of 2025.Declared a cash dividend of $0.18 per share for the first quarter of 2025.Reported revenues of $427.9 million for the first quarter of 2025.Achieved average daily spot time char...
- ABGSC Construct. & Real Estate Research
- Åsne Holsen
- Bengt Jonassen
- ABGSC Construct. & Real Estate Research
- Åsne Holsen
- Bengt Jonassen
- ABGSC Construct. & Real Estate Research
- Åsne Holsen
- Bengt Jonassen
FRO – Invitation to Q1 2025 Results Conference Call and Webcast
FRO – Invitation to Q1 2025 Results Conference Call and Webcast Frontline plc.’s preliminary first quarter 2025 results will be released on Friday May 23, 2025, and a webcast and conference call will be held at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time). The results presentation will be available for download from the Investor Relations section at ahead of the conference call. In order to attend the conference call you may do one of the following: a. Webcast Go to the Investor Relations section at and follow the “Webcast” link, or access directly from the link below. b. Conference C...
- ABGSC Renewable Energy Research
- Åsne Holsen
- Daniel Vårdal Haugland
- ABGSC Construct. & Real Estate Research
- Åsne Holsen
- Bengt Jonassen
- ABGSC Renewable Energy Research
- Åsne Holsen
- Daniel Vårdal Haugland
Novo Nordisk AS: 1 director
A director at Novo Nordisk AS sold 40,000 shares at 450.528DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
- Rune Majlund Dahl
Zealand Pharma (Buy, TP: DKK950.00) - Dapiglutide likely next catalyst
Q1 revenue missed expectations on lower reimbursement revenue, while operating profit was a beat, as opex was below our forecast and consensus. The 2025 guidance was maintained for opex of DKK2,000m–2,500m. We believe the next potential share-price catalyst is the top-line results from the phase Ib dapiglutide trial in Q2e. We reiterate our BUY, but have cut our target price to DKK950 (1,000).
- Rune Majlund Dahl
Novo Nordisk (Buy, TP: DKK900.00) - Accelerated Wegovy roll-out ahead
Q1 LCY figures beat our forecasts, while the 2025 guidance was cut to 13–21% LCY sales growth YOY and 16–24% LCY operating profit growth YOY due to weaker GLP-1 sales. We have lowered our rebate for US Ozempic but maintain our 52% Wegovy rebate (in line with the Q1 rebate when adjusting for de-stocking). We reiterate our BUY and DKK900 target price.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.